SB44 (canakinumab biosimilar) / Samsung - LARVOL DELTA

Samsung Bioepis and Teva Expand Strategic Partnership to Advance Up to Six Potential Biosimilar Candidates (Teva Press Release) - "The agreement covers SB41, a potential biosimilar candidate referencing Fasenra (benralizumab), and SB44, a potential biosimilar candidate referencing Ilaris (canakinumab) with an option for 4 additional assets...Under the terms of the agreement, Samsung Bioepis will be responsible for the development, regulatory registration, and manufacture of the biosimilars, while Teva will be responsible for commercialization in global markets, including the United States (U.S.), Europe, and Canada. The companies have agreed to an option for expanding the partnership to other territories."

Licensing / partnership • Asthma • Eosinophilic Granulomatosis With Polyangiitis • Hypereosinophilic Syndrome • Inflammation